Ogsiveo has been specifically approved for use in adults with progressing desmoid tumours who require systemic treatment.
Each year, an estimated 1,650 people in the US are diagnosed with desmoid tumours, which may invade surrounding structures and organs, resulting in pain, mobility issues and decreased quality of life.
Although surgical removal has historically been the treatment of choice, desmoid tumours are associated with recurrence rates of up to 77% following surgical resection, and treatment guidelines now recommend systemic therapies as first-line intervention instead of surgery for most tumour locations requiring treatment.
